Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock Price Down 1.7%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) traded down 1.7% during mid-day trading on Tuesday . The stock traded as low as $26.51 and last traded at $26.51. Approximately 500 shares traded hands during trading, a decline of 28% from the average session volume of 695 shares. The stock had previously closed at $26.96.

Swedish Orphan Biovitrum AB (publ) Price Performance

The stock’s fifty day simple moving average is $25.66 and its 200 day simple moving average is $25.72. The company has a current ratio of 0.71, a quick ratio of 0.50 and a debt-to-equity ratio of 0.32.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) last posted its quarterly earnings data on Thursday, April 25th. The company reported $0.26 earnings per share (EPS) for the quarter. The firm had revenue of $601.91 million for the quarter. Swedish Orphan Biovitrum AB (publ) had a net margin of 9.29% and a return on equity of 7.92%.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.